{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T20:03:33Z","timestamp":1786133013844,"version":"build-2736575974"},"reference-count":48,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JASN"],"published-print":{"date-parts":[[2016,6]]},"abstract":"<jats:p>\n                    Locally produced 1,25-dihydroxyvitamin D3 may have pleiotropic effects outside of bone. Experimental and observational studies suggest that nutritional vitamin D may enhance erythropoiesis in settings of 25-hydroxy vitamin D (25(OH)D) deficiency. We conducted a double-blind, placebo-controlled, randomized clinical trial to assess the effects of supplementation with ergocalciferol on epoetin utilization and other secondary outcomes in patients on hemodialysis with serum 25(OH)D &lt;30 ng\/ml. In all, 276 patients were randomized to 6 months of ergocalciferol or placebo. Mean\u00b1SD serum 25(OH)D increased from 16.0\u00b15.9 ng\/ml at baseline to 39.2\u00b114.9 ng\/ml in the ergocalciferol arm and did not change (16.9\u00b16.4 ng\/ml and 17.5\u00b17.4 ng\/ml, respectively) in the placebo arm. There was no significant change in epoetin dose over 6 months in the ergocalciferol or placebo arms (geometric mean rate 0.98 [95% confidence interval (95% CI), 0.94 to 1.02] versus 0.99 [95% CI, 0.95 to 1.03], respectively) and no difference across arms (\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    =0.78). No change occurred in serum calcium, phosphorus, intact parathyroid hormone, or C-reactive protein levels, cinacalcet use, or phosphate binder or calcitriol dose in either study arm. Rates of all-cause, cardiovascular, and infection-related hospitalizations did not differ by study arm, although statistical power was limited for these outcomes. In conclusion, 6 months of supplementation with ergocalciferol increased serum 25(OH)D levels in patients on hemodialysis with vitamin D insufficiency or deficiency, but had no effect on epoetin utilization or secondary biochemical and clinical outcomes.\n                  <\/jats:p>","DOI":"10.1681\/asn.2015040468","type":"journal-article","created":{"date-parts":[[2015,12,18]],"date-time":"2015-12-18T00:04:16Z","timestamp":1450397056000},"page":"1801-1810","source":"Crossref","is-referenced-by-count":60,"title":["Ergocalciferol Supplementation in Hemodialysis Patients With Vitamin D Deficiency: A Randomized Clinical Trial"],"prefix":"10.1681","volume":"27","author":[{"given":"Dana C.","family":"Miskulin","sequence":"first","affiliation":[{"name":"Division of Nephrology, and"},{"name":"Tufts University School of Medicine, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Majchrzak","sequence":"additional","affiliation":[{"name":"Dialysis Clinic Inc., Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hocine","family":"Tighiouart","sequence":"additional","affiliation":[{"name":"Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts;"},{"name":"Tufts University School of Medicine, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Muther","sequence":"additional","affiliation":[{"name":"Kidney Associates of Kansas City, Kansas City, Missouri;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toros","family":"Kapoian","sequence":"additional","affiliation":[{"name":"Dialysis Clinic Inc., North Brunswick, New Jersey; and"},{"name":"Rutgers\u2013Robert Wood Johnson Medical School, New Brunswick, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doug S.","family":"Johnson","sequence":"additional","affiliation":[{"name":"Dialysis Clinic Inc., Nashville, Tennessee;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Weiner","sequence":"additional","affiliation":[{"name":"Division of Nephrology, and"},{"name":"Tufts University School of Medicine, Boston, Massachusetts;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2015,12,17]]},"reference":[{"key":"B1-20230819","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1172\/JCI110501","article-title":"Evidence for extrarenal production of 1 alpha, 25-dihydroxyvitamin D in man.","volume":"69","author":"Lambert","year":"1982","journal-title":"J Clin Invest"},{"key":"B2-20230819","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.abb.2012.02.016","article-title":"Extrarenal expression of the 25-hydroxyvitamin D-1-hydroxylase.","volume":"523","author":"Adams","year":"2012","journal-title":"Arch Biochem Biophys"},{"key":"B3-20230819","doi-asserted-by":"crossref","first-page":"98","DOI":"10.2215\/CJN.12941213","article-title":"Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study.","volume":"10","author":"Tentori","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B4-20230819","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1111\/sdi.12010","article-title":"Vitamin D in dialysis: defining deficiency and rationale for supplementation.","volume":"26","author":"Singer","year":"2013","journal-title":"Semin Dial"},{"key":"B5-20230819","first-page":"S1","article-title":"KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD).","volume":"113","year":"2009","journal-title":"Kidney Int Suppl"},{"key":"B6-20230819","doi-asserted-by":"crossref","first-page":"905","DOI":"10.2215\/CJN.06510909","article-title":"Cholecalciferol supplementation in hemodialysis patients: effects on mineral metabolism, inflammation, and cardiac dimension parameters.","volume":"5","author":"Matias","year":"2010","journal-title":"Clin J Am Soc Nephrol"},{"key":"B7-20230819","doi-asserted-by":"crossref","first-page":"98","DOI":"10.5301\/JN.2010.1830","article-title":"Vitamin D supplementation and recombinant human erythropoietin utilization in vitamin D-deficient hemodialysis patients.","volume":"24","author":"Kumar","year":"2011","journal-title":"J Nephrol"},{"key":"B8-20230819","doi-asserted-by":"crossref","first-page":"c132","DOI":"10.1159\/000098645","article-title":"Prevalence of vitamin D deficiency and the safety and effectiveness of monthly ergocalciferol in hemodialysis patients.","volume":"105","author":"Saab","year":"2007","journal-title":"Nephron Clin Pract"},{"key":"B9-20230819","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/sj.ki.5000045","article-title":"Vitamin D in chronic kidney disease: a systemic role for selective vitamin D receptor activation.","volume":"69","author":"Andress","year":"2006","journal-title":"Kidney Int"},{"key":"B10-20230819","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1159\/000202632","article-title":"25-Hydroxyvitamin D deficiency and inflammation and their association with hemoglobin levels in chronic kidney disease.","volume":"30","author":"Kendrick","year":"2009","journal-title":"Am J Nephrol"},{"key":"B11-20230819","doi-asserted-by":"crossref","first-page":"c373","DOI":"10.1159\/000321521","article-title":"Serum 25(OH)-cholecalciferol concentration is associated with hemoglobin level and erythropoietin resistance in patients on maintenance hemodialysis.","volume":"117","author":"Kiss","year":"2011","journal-title":"Nephron Clin Pract"},{"key":"B12-20230819","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/ki.2009.551","article-title":"Vitamin D deficiency and anemia in early chronic kidney disease.","volume":"77","author":"Patel","year":"2010","journal-title":"Kidney Int"},{"key":"B13-20230819","doi-asserted-by":"crossref","first-page":"c121","DOI":"10.1159\/000074837","article-title":"Calcitriol increases burst-forming unit-erythroid proliferation in chronic renal failure. A synergistic effect with r-HuEpo.","volume":"95","author":"Aucella","year":"2003","journal-title":"Nephron Clin Pract"},{"key":"B14-20230819","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1093\/ndt\/gft021","article-title":"Renal anaemia and EPO hyporesponsiveness associated with vitamin D deficiency: the potential role of inflammation.","volume":"28","author":"Icardi","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B15-20230819","first-page":"19","article-title":"The role of vitamin D in regulating the iron-hepcidin-ferroportin axis in monocytes.","volume":"1","author":"Zughaier","year":"2014","journal-title":"J Clin Transl Endocrinol"},{"key":"B16-20230819","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1016\/S0140-6736(09)60502-X","article-title":"Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials.","volume":"373","author":"Bohlius","year":"2009","journal-title":"Lancet"},{"key":"B17-20230819","doi-asserted-by":"crossref","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","article-title":"Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease.","volume":"153","author":"Palmer","year":"2010","journal-title":"Ann Intern Med"},{"key":"B18-20230819","doi-asserted-by":"crossref","first-page":"3799","DOI":"10.1093\/ndt\/gfp370","article-title":"Monthly cholecalciferol administration in haemodialysis patients: a simple and efficient strategy for vitamin D supplementation.","volume":"24","author":"Jean","year":"2009","journal-title":"Nephrol Dial Transplant"},{"key":"B19-20230819","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.2215\/CJN.12761211","article-title":"25-Hydroxyvitamin D response to cholecalciferol supplementation in hemodialysis.","volume":"7","author":"Armas","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"B20-20230819","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1159\/000081023","article-title":"Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study.","volume":"24","author":"Gonz\u00e1lez","year":"2004","journal-title":"Am J Nephrol"},{"key":"B21-20230819","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.2215\/CJN.02840312","article-title":"Effects of cholecalciferol on functional, biochemical, vascular, and quality of life outcomes in hemodialysis patients.","volume":"8","author":"Hewitt","year":"2013","journal-title":"Clin J Am Soc Nephrol"},{"key":"B22-20230819","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1053\/j.ajkd.2014.04.020","article-title":"Biochemical parameters after cholecalciferol repletion in hemodialysis: results From the VitaDial randomized trial.","volume":"64","author":"Massart","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"B23-20230819","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1471-2369-15-50","article-title":"Cardiovascular effects of cholecalciferol treatment in dialysis patients--a randomized controlled trial.","volume":"15","author":"Mose","year":"2014","journal-title":"BMC Nephrol"},{"key":"B24-20230819","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1159\/000354717","article-title":"Influence of cholecalciferol supplementation in hemodialysis patients on monocyte subsets: a randomized, double-blind, placebo-controlled clinical trial.","volume":"123","author":"Seibert","year":"2013","journal-title":"Nephron Clin Pract"},{"key":"B25-20230819","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.jrn.2012.12.007","article-title":"The effect of ergocalciferol on uremic pruritus severity: a randomized controlled trial.","volume":"23","author":"Shirazian","year":"2013","journal-title":"J Ren Nutr"},{"key":"B26-20230819","first-page":"77","article-title":"Double treatment with paricalcitol-associated calcifediol and cardiovascular risk biomarkers in haemodialysis.","volume":"33","author":"Pi\u00f1era-Haces","year":"2013","journal-title":"Nefrologia"},{"key":"B27-20230819","doi-asserted-by":"crossref","first-page":"522","DOI":"10.3945\/ajcn.111.025502","article-title":"Efficacy and safety of a short course of very-high-dose cholecalciferol in hemodialysis.","volume":"95","author":"Wasse","year":"2012","journal-title":"Am J Clin Nutr"},{"key":"B28-20230819","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S2213-8587(13)70165-7","article-title":"Vitamin D status and ill health: a systematic review.","volume":"2","author":"Autier","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B29-20230819","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00011-014-0755-z","article-title":"Inflammation and vitamin D: the infection connection.","volume":"63","author":"Mangin","year":"2014","journal-title":"Inflamm Res"},{"key":"B30-20230819","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1016\/S0140-6736(10)61032-X","article-title":"Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial.","volume":"376","author":"de Zeeuw","year":"2010","journal-title":"Lancet"},{"key":"B31-20230819","doi-asserted-by":"crossref","first-page":"3523","DOI":"10.1093\/ndt\/gfs138","article-title":"Randomized controlled trial of cholecalciferol supplementation in chronic kidney disease patients with hypovitaminosis D.","volume":"27","author":"Marckmann","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"B32-20230819","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1136\/jclinpath-2012-201301","article-title":"Vitamin D: a negative acute phase reactant.","volume":"66","author":"Waldron","year":"2013","journal-title":"J Clin Pathol"},{"key":"B33-20230819","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1093\/ndt\/gft001","article-title":"Cholecalciferol in haemodialysis patients: a randomized, double-blind, proof-of-concept and safety study.","volume":"28","author":"Delanaye","year":"2013","journal-title":"Nephrol Dial Transplant"},{"key":"B34-20230819","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1007\/s00467-013-2431-x","article-title":"Ergocalciferol decreases erythropoietin resistance in children with chronic kidney disease stage 5.","volume":"28","author":"Rianthavorn","year":"2013","journal-title":"Pediatr Nephrol"},{"key":"B35-20230819","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2215\/CJN.06910714","article-title":"Nutritional vitamin D supplementation in dialysis: a randomized trial.","volume":"10","author":"Bhan","year":"2015","journal-title":"Clin J Am Soc Nephrol"},{"key":"B36-20230819","doi-asserted-by":"crossref","first-page":"10","DOI":"10.4158\/EP.14.1.10","article-title":"Cholecalciferol (vitamin D3) therapy and vitamin D insufficiency in patients with chronic kidney disease: a randomized controlled pilot study.","volume":"14","author":"Chandra","year":"2008","journal-title":"Endocr Pract"},{"key":"B37-20230819","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1053\/j.ajkd.2011.06.027","article-title":"Paricalcitol versus ergocalciferol for secondary hyperparathyroidism in CKD stages 3 and 4: a randomized controlled trial.","volume":"59","author":"Kovesdy","year":"2012","journal-title":"Am J Kidney Dis"},{"issue":"4","key":"B38-20230819","first-page":"CD005633","article-title":"Vitamin D compounds for people with chronic kidney disease requiring dialysis.","author":"Palmer","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"B39-20230819","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/s11255-011-0048-1","article-title":"Effect of nutritional vitamin D preparations on parathyroid hormone in patients with chronic kidney disease.","volume":"44","author":"Pipili","year":"2012","journal-title":"Int Urol Nephrol"},{"key":"B40-20230819","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1161\/CIRCRESAHA.113.301241","article-title":"Vitamin D and cardiovascular disease.","volume":"114","author":"Norman","year":"2014","journal-title":"Circ Res"},{"key":"B41-20230819","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.ijcard.2013.08.055","article-title":"Effect of calcium or vitamin D supplementation on vascular outcomes: a meta-analysis of randomized controlled trials.","volume":"169","author":"Mao","year":"2013","journal-title":"Int J Cardiol"},{"key":"B42-20230819","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/S2213-8587(13)70212-2","article-title":"The effect of vitamin D supplementation on skeletal, vascular, or cancer outcomes: a trial sequential meta-analysis.","volume":"2","author":"Bolland","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"B43-20230819","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1053\/j.ajkd.2011.12.035","article-title":"Ergocalciferol and cholecalciferol in CKD.","volume":"60","author":"Nigwekar","year":"2012","journal-title":"Am J Kidney Dis"},{"key":"B44-20230819","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1001\/jama.2010.594","article-title":"Annual high-dose oral vitamin D and falls and fractures in older women: a randomized controlled trial.","volume":"303","author":"Sanders","year":"2010","journal-title":"JAMA"},{"key":"B45-20230819","doi-asserted-by":"crossref","first-page":"g4452","DOI":"10.1136\/bmj.g4452","article-title":"Are trials of vitamin D with mortality as an endpoint really needed?","volume":"349","author":"Bolland","year":"2014","journal-title":"BMJ"},{"key":"B46-20230819","first-page":"CD004289","article-title":"HMG CoA reductase inhibitors (statins) for dialysis patients.","volume":"9","author":"Palmer","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"B47-20230819","doi-asserted-by":"crossref","first-page":"1991","DOI":"10.1056\/NEJMoa1306357","article-title":"Vitamin D-binding protein and vitamin D status of black Americans and white Americans.","volume":"369","author":"Powe","year":"2013","journal-title":"N Engl J Med"},{"key":"B48-20230819","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1525-139X.2011.00849.x","article-title":"The phosphate binder equivalent dose.","volume":"24","author":"Daugirdas","year":"2011","journal-title":"Semin Dial"}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00001751-201606000-00026","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T19:27:24Z","timestamp":1786130844000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00001751-201606000-00026"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12,17]]},"references-count":48,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016]]}},"URL":"https:\/\/doi.org\/10.1681\/asn.2015040468","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,12,17]]}}}